CAP-1002: Phase I/II ongoing

An independent DSMB recommended continuation of the open-label, U.S. Phase I/II HOPE-Duchenne trial evaluating intracoronary infusions of CAP-1002 into each of the 3 left ventricle cardiac territories based on a review of the first patient cohort. The trial is enrolling about 24 male patients. If all 3 arteries are infused, each patient will receive 50-75 million cells. ...